Director, Controller

About this role

About us:

Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart’s goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, reversibility and reducing prescribing complexity.

With a proven leadership team, a strong financial foundation, and a high-value late-stage asset, Braveheart Bio represents an outstanding opportunity for ambitious, mission-driven professionals to make a tangible impact in a high-profile and rapidly evolving therapeutic area.

The role:

The Director, Controller is an experienced leader that will build and run the financial infrastructure of our fast-moving clinical-stage biotechnology company. Reporting to the VP of Finance, this individual will own day-to-day accounting operations and related internal controls, including month-end, quarter-end, and year-end close processes, as well as lead necessary system implementations to support the Company’s continued growth. This is a hands-on role that will collaborate with various internal and external partners, including non-finance operating teams.

Key responsibilities:

• Own the monthly, quarterly, and annual close process to ensure accurate financial statements on a timeline that meets internal and external reporting deadlines.